Molecular genetic laboratory GENNET investigates patients with oncopanel of genes for hereditary cancers CZECANCA (CZEch CAncer paNel for Clinical Application), which was established by a group of Dr. Kleibl from the Institute of Biochemistry and Experimental Oncology of 1st Medical Faculty of Charles University in Prague. The panel includes 219 target genes for investigation of hereditary malignities using the technique of next generation sequencing (NGS Next Generation Sequencing). It allows for primary analysis of all 44 recognized susceptibility genes (e.g. BRCA1, BRCA2, CHEK2, TP53, PALB2, ATM, MLH1, MSH2, MSH6, EPCAM and MUTYH). Their mutations cause hereditary cancer, such as syndrome of hereditary breast cancer and ovarian cancer, syndromes with cancer of digestive tract or syndrome of familial melanoma and many others. Other genes involved in the panel represent candidate genes for preclinical studies within the Czech population.
What are the reasons for using OCOPANEL for examination?
The advantage of the use of the panel is the possibility of examination of multiple genes in a single laboratory test. Mutations in various genes may in fact be the cause of the same cancer and a certain type of tumor may develop on the basis of a predisposition caused by mutations (changes) in different genes. Thus, this method reduces the time of examination and is even more economical than the usual examination of sequential analysis of individual genes.
The detected mutation is always verified by sequencing from a second independent DNA sample of the patient.